The incidence of symptomatic CSF viral escape in patients on antiretroviral therapy in western India: a retrospective cohort study
Journal of NeuroVirology · 2025
DOI: 10.1007/s13365-024-01236-5 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Journal of NeuroVirology, 2025. Verfasst von Atul Patel und 4 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases Department, Sterling Hospital, Ahmedabad, 380052, India. atulpatel65@gmail.com. Hauptthemen laut MEDLINE: HIV Infections, HIV-1, Anti-HIV Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben.
Abstract (Originalsprache)
Antiretroviral treatment (ART) effectively suppresses viral loads in both plasma and cerebrospinal fluid (CSF). Patients with discordant plasma and CSF viral loads may experience chronic-progressive or fluctuating neurocognitive dysfunctions. This study examined the incidence of symptomatic CSF viral escape (CSFVE) in patients receiving ART. This retrospective cohort study was conducted between 2000 and 2023. The primary outcome measure was the incidence of symptomatic CSFVE. Nonparametric Mann-Whitney U and Fisher exact/χ 2 tests were applied for continuous and categorical variables, respectively. The cumulative incidence function with Gray's test was used to compare the incidence of CSFVE across the treatment regimens. During the study period, 52 of the 8415 patients were diagnosed with CSFVE. The median duration of HIV diagnosis in patients with CSF VE was 150 (12-288) months, with a median nadir CD4 + T-cell count 96.5 (13-601 cells/L)], and 75% of the patients were on a ritonavir-boosted protease inhibitor (PI/r) regimen. The cumulative incidence of symptomatic CSFVE at a follow-up of 14 years was 1% (95% CI, 0-1%). PI/r (HR 34.73; 95% CI 13.5 to 89.4; p < 0.001) and integrase strand transfer inhibitor (INSTI) (HR 3.42; 95% CI 1.94 to 6.02; p < 0.001) regimens were significantly more likely to be associated with CSFVE than the Non-nucleoside reverse transcriptase inhibitors (NNRTIs) regimens. NNRTIs had the lowest risk of CSFVE compared to the PI/r and INSTI regimens. A rapid and complete recovery is possible with symptomatic CSFVE if it is diagnosed and treated early.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Infectious Diseases Department, Sterling Hospital, Ahmedabad, 380052, India. atulpatel65@gmail.com.
- Department of Internal Medicine, Division of Infectious Diseases, USF, Tampa, FL, USA. atulpatel65@gmail.com.
- Infectious Diseases Department, Sterling Hospital, Ahmedabad, 380052, India.
- GMERS Medical College, Sola, Ahmedabad, 380060, India.
- Research Methodology and Biostatistics Core, Office of Research, Department of Internal Medicine, Morsani College Of Medicine, University of South Florida, Tampa, FL, USA.
Zitieren
APA
Patel, A., Patel, K., Patel, N., Shah, K., & Kumar, A. (2025). The incidence of symptomatic CSF viral escape in patients on antiretroviral therapy in western India: a retrospective cohort study. Journal of NeuroVirology. https://doi.org/10.1007/s13365-024-01236-5
Vancouver
Patel A, Patel K, Patel N, Shah K, Kumar A. The incidence of symptomatic CSF viral escape in patients on antiretroviral therapy in western India: a retrospective cohort study. Journal of NeuroVirology. 2025. doi:10.1007/s13365-024-01236-5
BibTeX
@article{Patel2025,
author = {Patel, Atul and Patel, Ketan and Patel, Niyati and Shah, Kinjal and Kumar, Ambuj},
title = {The incidence of symptomatic CSF viral escape in patients on antiretroviral therapy in western India: a retrospective cohort study},
journal = {Journal of NeuroVirology},
year = {2025},
doi = {10.1007/s13365-024-01236-5}
}
EUVIMED